中草药

黄连-吴茱萸药对中生物碱成分改善三阴性乳腺癌的作用机制研究进展

PDF下载

中草药 | 综述 2026,57(13): 5330-5343

收起

中草药 |综述 2026 , 57 (13) : 5330 -5343

黄连-吴茱萸药对中生物碱成分改善三阴性乳腺癌的作用机制研究进展

全屏

赵倩^1,2, 罗婧溪¹, 于瀚¹, 彭成^1,2, 韩波², 黄维²

作者信息

通讯作者:

黄维

作者简介:

赵倩: 赵倩，女，副教授，博士，主要从事中药及复方物质基础与多维配伍研究。E-mail:zhaoqian@cdutcm.edu.cn

Research progress on mechanisms of alkaloids from Coptidis Rhizoma-Euodiae Fructus herb pair in ameliorating triple-negative breast cancer

ZHAO Qian, LUO Jingxi, YU Han, PENG Cheng, HAN Bo, HUANG Wei

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.13.033

文章导航

摘要

收起

三阴性乳腺癌（triple-negative breast cancer，TNBC）是雌激素受体、孕激素受体和人表皮生长因子受体2表达均为阴性的乳腺癌亚型，具有侵袭性强、复发转移率高、预后差的特点，目前缺乏有效的靶向治疗手段。黄连-吴茱萸是中医药经典药对，其主要活性成分包括小檗碱、黄连碱、吴茱萸碱、吴茱萸次碱等生物碱类化合物。近年来，黄连-吴茱萸药对在抗肿瘤领域展现出巨大潜力，而越来越多的研究关注到二者生物碱类活性成分在改善TNBC方面的药理作用。基于此，梳理了黄连与吴茱萸的生物碱类活性成分，重点从抑制细胞侵袭与转移、影响细胞周期、诱导细胞凋亡等多个维度阐述了近年来其主要活性成分改善TNBC的作用机制，以期为黄连-吴茱萸药对进一步的开发利用提供参考，为中医药防治TNBC提供新的思路和科学依据。

关键词

黄连 / 吴茱萸 / 生物碱 / 三阴性乳腺癌 / 作用机制 / 细胞侵袭与转移 / 细胞周期 / 细胞凋亡

Abstract

收起

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. It exhibits high invasiveness, elevated rates of recurrence and metastasis, poor prognosis, and currently lacks effective targeted therapeutic approaches. The Coptidis Rhizoma-Euodiae Fructus herb pair is a classic Traditional Chinese Medicine (TCM), its major active components include alkaloid compounds such as berberine, coptisine, evodiamine, and rutaecarpine. In recent years, Coptidis Rhizoma-Euodiae Fructus herb pair has demonstrated tremendous potential in the field of anti-tumor therapy, with increasing research focusing on the pharmacological effects of their alkaloid components in ameliorating TNBC. Accordingly, this review briefly summarizes the alkaloid components of Coptidis Rhizoma and Euodiae Fructus, emphasizing their mechanisms of action in enhancing TNBC treatment, which include inhibiting cell invasion and metastasis, regulating the cell cycle, and inducing apoptosis. This aims to provide references for the further development and utilization of the Coptidis Rhizoma-Euodiae Fructus herb pair and to offer new insights and scientific evidence for the application of TCM in the prevention and treatment of TNBC.

Key words

Coptidis Rhizoma / Euodiae Fructus / alkaloids / triple-negative breast cancer / mechanisms of action / cell invasion and metastasis / cell cycle / apoptosis

引用本文

赵倩, 罗婧溪, 于瀚, 彭成, 韩波, 黄维. 黄连-吴茱萸药对中生物碱成分改善三阴性乳腺癌的作用机制研究进展. 中草药, 2026 , 57 (13) : 5330 -5343 . DOI: 10.7501/j.issn.0253-2670.2026.13.033

ZHAO Qian, LUO Jingxi, YU Han, PENG Cheng, HAN Bo, HUANG Wei. Research progress on mechanisms of alkaloids from Coptidis Rhizoma-Euodiae Fructus herb pair in ameliorating triple-negative breast cancer[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (13) : 5330 -5343 . DOI: 10.7501/j.issn.0253-2670.2026.13.033

基金

收起

国家自然科学基金面上项目 (82574707,82374155); 四川省科技厅项目 (2024YFFK0092)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Zhang Y, Ji Y, Liu S, et al. Global burden of female breast cancer: New estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN [J]. J Natl Cancer Cent, 2025, 5(3): 287-296.
Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer: Expanded options, evolving needs [J]. Nat Rev Clin Oncol, 2022, 19(2): 91-113.
Britt K L, Cuzick J, Phillips K A. Key steps for effective breast cancer prevention [J]. Nat Rev Cancer, 2020, 20(8): 417-436.
Liao M R, Qin R, Huang W, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: A revisited perspective from molecular mechanisms to targeted therapies [J]. J Hematol Oncol, 2022, 15(1): 44.
赵志娟, 肖君. 左金丸治疗消化系统疾病的临床研究进展 [J]. 中国医学创新, 2022, 19(10): 185-188.
郭祖正, 王钰, 曹志群, 等. 左金丸治疗胃食管反流病的研究进展 [J]. 西部中医药, 2025, 38(1): 119-122.
Wang X Y, Tang G H, Guo H, et al. Research progress on the anti-tumor mechanism and reversal of multidrug resistance of Zuojin Pill and its main components, evodiamine and berberine [J]. Nat Prod Commun, 2023, 18(3): 1934578X231161414.
刘树森, 孙文斌, 李文兰, 等. 基于网络药理学的黄连-吴茱萸药对抗癌及治疗心脑血管疾病机制研究 [J]. 中草药, 2020, 51(1): 109-117.
张汗顺, 谢斌, 余功. 左金丸抗肿瘤作用机制研究进展 [J]. 江西中医药大学学报, 2024, 36(5): 108-111.
刘霜, 旺建伟. 左金丸及其主要单体成分抗结直肠癌机制的研究进展 [J]. 中国实验方剂学杂志, 2023, 29(22): 204-214.
褚璨灿, 师为人, 陈云志, 等. 左金丸临床应用与实验研究进展 [J]. 实用中医药杂志, 2019, 35(5): 626-629.
卢雯平, 王笑民, 马飞. 乳腺癌中西医结合诊疗指南 [J]. 北京中医药, 2024, 43(1): 7-16.
江丰, 李彬, 郑文科, 等. 辛开苦降之法调理枢机之效: 张伯礼教授临床应用左金丸举隅 [J]. 天津中医药, 2014, 31(8): 451-452.
奉永兰. 左金丸加味治疗肿瘤患者化疗后吐酸36例疗效观察 [J]. 四川中医, 2013, 31(5): 89-90.
程剑, 肖龙生, 张虹, 等. 左金丸粉剂外敷涌泉穴联合格拉司琼与单用格拉司琼治疗肿瘤化疗后恶心呕吐疗效比较 [J]. 系统医学, 2020, 5(15): 109-111.
姚颖. 三阴性乳腺癌藏象辨证规律研究 [D]. 南京: 南京中医药大学, 2019.
盖晓红, 刘素香, 任涛, 等. 黄连的化学成分及药理作用研究进展 [J]. 中草药, 2018, 49(20): 4919-4927.
周瑞, 项昌培, 张晶晶, 等. 黄连化学成分及小檗碱药理作用研究进展 [J]. 中国中药杂志, 2020, 45(19): 4561-4573.
孔奕丹, 齐英, 崔娜, 等. 吴茱萸化学成分及药理作用研究进展 [J]. 中医药信息, 2023, 40(5): 79-83.
何宁, 马珍珍, 王秋月, 等. 有毒中药吴茱萸及减毒配伍研究探讨 [J]. 中草药, 2024, 55(6): 1812-1838.
彭明兴, 吴永江, 程翼宇. 黄连与吴茱萸配伍时黄连中主要化学组分溶出率变化规律研究 [J]. 中国中药杂志, 2003, 28(7): 629-632.
陈锐娥, 胡杨洋, 王胜鹏, 等. 中药药对的系统研究(Ⅳ): 黄连吴茱萸药对研究 [J]. 世界科学技术-中医药现代化, 2012, 14(2): 1334-1341.
涂瑶生, 刘法锦, 孙冬梅, 等. 黄连、吴茱萸配伍药对的HPLC指纹图谱研究 [J]. 中成药, 2011, 33(1): 5-9.
彭求贤, 蔡红兵, 史珏, 等. 黄连配伍吴茱萸后生物碱类成分的含量变化 [J]. 中药材, 2012, 35(5): 742-744.
王旭, 徐蓓蕾, 吴迪, 等. 不同配伍比例的黄连-吴茱萸药对研究进展 [J]. 中国实验方剂学杂志, 2020, 26(3): 21-30.
Qian P, Jin H W, Yang X W. New limonoids from Coptidis Rhizoma–Euodiae Fructus couple [J]. J Asian Nat Prod Res, 2014, 16(4): 333-344.
Du J, Sun Y, Wang X F, et al. Establishment of an experimental breast cancer ZHENG model and curative effect evaluation of Zuo-Jin Wan [J]. Evid Based Complementary Altern Med, 2013, 2013: 324732.
杜佳, 孙阳, 周钱梅, 等. 左金丸药物血清对人乳腺癌MCF-7细胞周期和细胞凋亡的影响 [J]. 时珍国医国药, 2016, 27(11): 2604-2606.
朱会宇, 刘雅琳, 王思嘉, 等. 左金丸水提取液提高ATG4B含量促进自噬抑制三阴性乳腺癌进展 [J]. 北京工业大学学报, 2025, 51(8): 995-1003.
Kim S, Lee J, You D, et al. Berberine suppresses cell motility through downregulation of TGF-β1 in triple negative breast cancer cells [J]. Cell Physiol Biochem, 2018, 45(2): 795-807.
Kim S, Choi J H, Bin Kim J, et al. Berberine suppresses TNF-α-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells [J]. Molecules, 2008, 13(12): 2975-2985.
Jeong Y, You D, Kang H G, et al. Berberine suppresses fibronectin expression through inhibition of c-Jun phosphorylation in breast cancer cells [J]. J Breast Cancer, 2018, 21(1): 21.
Du Y S, Khan M, Fang N N, et al. Berberine attenuates cell motility via inhibiting inflammation-mediated lysyl hydroxylase-2 and glycolysis [J]. Front Pharmacol, 2022, 13: 856777.
杨喜燕, 焦红军, 周建华, 等. 黄连素通过下调VEGF表达抑制三阴性乳腺癌生长实验研究 [J]. 亚太传统医药, 2025, 21(10): 38-44.
Sun Y F, Zhou Q Q, Chen F M, et al. Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites [J]. Pharmacol Res, 2023, 193: 106817.
李想, 石海莲, 谢建群, 等. 吴茱萸碱对MDA-MB-231细胞增殖迁移及IL-8表达的影响 [J]. 中药药理与临床, 2014, 30(3): 27-30.
Du J, Wang X F, Zhou Q M, et al. Evodiamine induces apoptosis and inhibits metastasis in MDA-MB-231 human breast cancer cells in vitro and in vivo [J]. Oncol Rep, 2013, 30(2): 685-694.
Li X, Zhao S J, Shi H L, et al. Berberine hydrochloride IL-8 dependently inhibits invasion and IL-8-independently promotes cell apoptosis in MDA-MB-231 cells [J]. Oncol Rep, 2014, 32(6): 2777-2788.
吴焱, 李想, 石海莲. 盐酸小檗碱与吴茱萸碱联用抑制乳腺癌转移的作用机制 [J]. 中国临床药理学杂志, 2015, 31(12): 1165-1168.
Dian L L, Xu Z Z, Sun Y F, et al. Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/β-catenin signaling and EMT [J]. Phytochemistry, 2022, 200: 113217.
Sun Y F, Gao X Y, Wu P P, et al. Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT) [J]. Phytomedicine, 2019, 63: 153015.
王斌, 许诗雨, 刘嘉欣, 等. 黄连总生物碱联合运动通过阻滞细胞周期G1/S转换抑制原位移植4T1乳腺癌小鼠荷瘤生长的研究 [J]. 中国中药杂志, 2019, 44(8): 1635-1641.
Lin Y S, Chiu Y C, Tsai Y H, et al. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines [J]. J Cell Biochem, 2019, 120(8): 13531-13544.
El Khalki L, Maire V, Dubois T, et al. Berberine impairs the survival of triple negative breast cancer cells: Cellular and molecular analyses [J]. Molecules, 2020, 25(3): 506.
Kim J B, Yu J H, Ko E, et al. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest [J]. Phytomedicine, 2010, 17(6): 436-440.
Tak J, Sabarwal A, Shyanti R K, et al. Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt [J]. Mol Cell Biochem, 2019, 458(1): 49-59.
李静, 曹素萍. 黄连碱对人乳腺癌MDA-MB-231细胞周期和增殖的作用及其机制 [J]. 江苏医药, 2015, 41(9): 1002-1004.
Ativui S, Danquah C A, Osafo N, et al. Palmatine modulates triple negative mammary carcinoma by regulating the endogenous function of p53, p21 and Mdm2 [J]. Biomed Pharmacol J, 2021, 14(2): 943-954.
Han S, Woo J K, Jung Y, et al. Evodiamine selectively targets cancer stem-like cells through the p53-p21-Rb pathway [J]. Biochem Biophys Res Commun, 2016, 469(4): 1153-1158.
Du J, Sun Y, Lu YY, et al. Berberine and evodiamine act synergistically against human breast cancer MCF-7 cells by inducing cell cycle arrest and apoptosis [J]. Anticancer Res, 2017, 37(11): 6141-6151.
秦田, 杨宇石, 尹明英, 等. 小檗碱对三阴性乳腺癌细胞MDA-MB-231增殖、迁移及凋亡的影响 [J]. 贵州医科大学学报, 2024, 49(2): 179-184.
谢娟, 黄新艳, 许银燕, 等. 盐酸小檗碱抑制乳腺癌MDA-MB-231细胞增殖及诱导凋亡的作用研究 [J]. 南京医科大学学报: 自然科学版, 2013, 33(9): 1220-1225.
Xie J, Xu Y Y, Huang X Y, et al. Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway [J]. Tumor Biol, 2015, 36(2): 1279-1288.
Zhao Y W, Jing Z L, Lv J, et al. Berberine activates Caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo [J]. Biomed Pharmacother, 2017, 95: 18-24.
秦田, 杨宇石, 尹明英, 等. 小檗碱通过SIRT2介导NF-κB乙酰化对三阴性乳腺癌MDA-MB-231细胞凋亡的影响 [J]. 贵州医科大学学报, 2024, 49(5): 658-664.
Sun Y, Wang W T, Tong Y W. Berberine inhibits proliferative ability of breast cancer cells by reducing metadherin [J]. Med Sci Monit, 2019, 25: 9058-9066.
Jabbarzadeh Kaboli P, Leong M P, Ismail P, et al. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study [J]. Pharmacol Rep, 2019, 71(1): 13-23.
Sun Y X, Li C, Yin H, et al. Berberine sensitises breast cancer cells to radiation via the attenuation of DNA ligase III [J]. J Cellular Molecular Medi, 2025, 29(17): e70836.
Ma W Y, Zhang Y R, Yu M, et al. In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects [J]. Int Immunopharmacol, 2020, 87: 106787.
Wang K L, Hsia S M, Yeh J Y, et al. Anti-proliferative effects of evodiamine on human breast cancer cells [J]. PLoS One, 2013, 8(6): e67297.
Shen Y F, Yang Y, Wang Z, et al. Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I [J]. British J Pharmacology, 2024, 181(21): 4262-4278.
Zhao L N, Zhang C H. Berberine inhibits MDA-MB-231 cells by attenuating their inflammatory responses [J]. BioMed Res Int, 2020, 2020: 3617514.
Yao M J, Fan X D, Yuan B, et al. Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell [J]. BMC Complementary Altern Med, 2019, 19(1): 216.
Kim S, You D, Jeong Y, et al. Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ ERK pathway in triple-negative breast cancer cells [J]. Phytomedicine, 2018, 50: 43-49.
Du Y S, Khan M, Fang N N, et al. Berberine attenuates cell motility via inhibiting inflammation-mediated lysyl hydroxylase-2 and glycolysis [J]. Front Pharmacol, 2022, 13: 856777.
赵文佳. 小檗碱药理作用对乳腺癌MDA-MB-231细胞的影响 [J]. 社区医学杂志, 2016, 14(17): 21-23.
Zhu C Y, Li J P, Hua Y M, et al. Berberine inhibits the expression of SCT through miR-214-3p stimulation in breast cancer cells [J]. Evid Based Complementary Altern Med, 2020, 2020: 2817147.
Ibrahim N, Alsadi N, Yasavoli-Sharahi H, et al. Berberine inhibits breast cancer stem cell development and decreases inflammation: Involvement of miRNAs and IL-6 [J]. Curr Dev Nutr, 2025, 9(2): 104532.
Xiong Y, Xiong C, Li P, et al. Rutaecarpine prevents the malignant biological properties of breast cancer cells by the miR-149-3p/S100A4 axis [J]. Ann Transl Med, 2022, 10(17): 930.
Fu W, Liu L X, Tong S J. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA [J]. Thorac Cancer, 2024, 15(17): 1357-1368.
Gao X J, Wang J, Li M Q, et al. Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs [J]. J Cellular Molecular Medi, 2019, 23(10): 6797-6804.
赵虹, 沃立科, 胡袁媛, 等. 黄连素抑制GRP78表达促进三阴乳腺癌细胞凋亡的研究 [J]. 浙江中医药大学学报, 2019, 43(5): 407-412.
Refaat A, Abdelhamed S, Yagita H, et al. Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer [J]. Oncol Lett, 2013, 6(3): 840-844.
Refaat A, Abdelhamed S, Saiki I, et al. Inhibition of p38 mitogen-activated protein kinase potentiates the apoptotic effect of berberine/tumor necrosis factor-related apoptosis-inducing ligand combination therapy [J]. Oncol Lett, 2015, 10(3): 1907-1911.
Eid S Y. Coptisine enhances the sensitivity of chemoresistant breast cancer cells by inhibiting the function and expression of ABC transporters [J]. Front Pharmacol, 2024, 15: 1472458.
任凯宁, 韩艺杰, 雷雪霏, 等. 黄连-吴茱萸药对传统汤剂与配方颗粒的药效对比研究 [J]. 中华中医药学刊, 2025, 43(5): 168-171.
Jabbarzadeh Kaboli P, Luo S, Chen Y, et al. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress [J]. Gene, 2022, 816: 146171.
Jin J K, Yoshimura K, Sewastjanow-Silva M, et al. Challenges and prospects of patient-derived xenografts for cancer research [J]. Cancers, 2023, 15(17): 4352.
Langhans S A. Using 3D in vitro cell culture models in anti-cancer drug discovery [J]. Expert Opin Drug Discov, 2021, 16(8): 841-850.
钱洁, 谭佳妮, 程海波, 等. 小檗碱对乳腺癌MDA-MB-231细胞增殖抑制作用及其分子机制研究 [J]. 天然产物研究与开发, 2019, 31(3): 422-427.
Xie J J, Du X, Li Y K, et al. Berberine shaping the tumor immune landscape via pyroptosis [J]. Cell Immunol, 2025, 408: 104908.
Lei J, Pan Y J, Gao R, et al. Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase [J]. J Transl Med, 2023, 21(1): 553.
李赞, 卫真真, 王子元, 等. 左金丸醇提物调控糖代谢改善结肠癌细胞西妥昔单抗抵抗的作用机制 [J]. 实用肿瘤杂志, 2023, 38(5): 439-446.
余彩雁, 靳淑颖, 周四桂, 等. 左金丸对IEC6、HCT116细胞共培养模型肠上皮屏障功能的保护及机制研究 [J]. 中药新药与临床药理, 2023, 34(1): 1-7.
Mao L Y, Chen Q Y, Gong K, et al. Berberine decelerates glucose metabolism via suppression of mTOR-dependent HIF-1α protein synthesis in colon cancer cells [J]. Oncol Rep, 2018: 2436-2442.
Du J, Sun Y, Lu Y Y, Lau E, et al. Berberine and evodiamine act synergistically against human breast cancer MCF-7 cells by inducing cell cycle arrest and apoptosis [J]. Anticancer Res, 2017, 37(11): 6141-6151.
Cui G L, Wang M L, Li X F, et al. Berberine in combination with evodiamine ameliorates gastroesophageal reflux disease through TAS2R38/TRPV1-mediated regulation of MAPK/NF-κB signaling pathways and macrophage polarization [J]. Phytomedicine, 2024, 135: 156251.
陈宁宁, 蒋义芳, 杨懿, 等. 小檗碱与吴茱萸碱联用对结直肠癌细胞迁移、侵袭能力的影响 [J]. 中国实验方剂学杂志, 2022, 28(24): 98-104.
Lin H M, Lin L F, Choi Y, et al. Development and in-vitro evaluation of co-loaded berberine chloride and evodiamine ethosomes for treatment of melanoma [J]. Int J Pharm, 2020, 581: 119278.
Guan X Y, Zheng X T, Vong C T, et al. Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro [J]. Eur J Pharmacol, 2020, 875: 173031.
Tao X Y, Gao Y F, Jin Z S, et al. Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment [J]. Phytomedicine, 2025, 147: 157185.
秦瑞博, 王洁雪, 陈方梅. 川黄连黄酮类成分抗氧化活性研究 [J]. 工业微生物, 2023, 53(2): 32-36.
尹丽, 彭苑霞, 陆华强. 吴茱萸挥发油研究进展 [J]. 广东化工, 2024, 51(24): 63-65.

2026年第57卷第13期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.13.033

接收时间：2025-12-26
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-12-26

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.13.033

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT